|
Home Page
About Us
Investors
Inventors
Portfolio
3DR Laboratories, LLC
AllTranz Inc.
AnosiaVax, Inc.
ApoImmune, Inc.
EndoProtech, Inc.
Eyevation, LLC
ImmunoTheragnostics Incorporated
InnoRem, Inc.
Intrepid Bioinformatics, Inc.
PGxl Laboratories, LLC
Pradama Inc.
RhinoCyte, Inc.
TrackFive Diagnostics, Inc.
ULSD, LLC
Contact Us
Privacy Policy
|
|
|
|
Portfolio - RhinoCyte, Inc.
| Incorporated: |
|
May 2005
|
| Contacts: |
|
Fred Roisen, Ph.D., Founder and President
|
| Description: |
|
RhinoCyte, Inc. is a biotechnology company founded in 2005 by Fred Roisen, Ph.D., Chair of the Department of Anatomical Sciences and Neurobiology at the University of Louisville. Dr. Roisen developed the technology with UofL researchers Kathleen Klueber, Ph.D. and Chengliang Lu, M.D.
The vision is that RhinoCyteTM will be a leader in the advancement of cell based therapies by providing innovative autologous adult human cell solutions to treat a variety of neurodegenerative disorders. These include spinal cord injuries (SCI), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). The RhinoCyteTM technology affords patients a novel cellular replacement therapy without immunosuppression.
RhinoCyte™ will initially focus its efforts on the treatment of subacute spinal cord injury. SCI affects more than 250,000 patients in the U.S. alone, with 13,000 new cases annually. According to the National Spinal Cord Injury Statistical Center, annual total costs for spinal cord injuries exceed $20 Billion.
While there are therapies that treat the symptoms resulting from SCI, they do not promote or provide anatomical or functional recovery. The cutting edge technology platform fueling the RhinoCyte™ SCI therapy changes the treatment paradigm by promoting both.
Through its partnership with MetaCyte, RhinoCyteTM raised a $930,000 Seed financing in June, 2007. The company also raised a Bridge financing of $730,000 in August 2008 to continue to fund key milestones. The company has entered the IND Enabling Stage for its lead product SCI and has had a first close on a Series A1 financing that represents $1.6 Million in new money. The aforementioned financings have enabled the company to advance the technology platform, develop new indications leveraging those advances, and file new patent applications covering these new indications. Patents have currently been granted in Australia and Israel.
|
| Other Resources: |
|
See coverage of Dr. Roisen's research at the University of Louisville at:
UofL Medicine Magazine: A UofL research team led by Fred Roisen, Ph.D., has developed a breakthrough adult stem-cell therapy that repairs spinal-cord damage in paralyzed rats (External Link)
|
|
|
